AI MARKET SCANNING

Immunovant Inc

📅 Next Catalyst: Nov 09, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP +0.07%
MAX GAP RECORD +15.79%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $IMVT
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 09, 2026 Earnings Release 2026-11-09 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
-3.31%
May 20, 2026 Earnings Release 2026-05-20 (BEFORE OPEN)
+15.79%
Feb 06, 2026 Earnings Release 2026-02-06 (BEFORE OPEN)
+11.72%
Nov 10, 2025 Earnings Release 2025-11-10 (BEFORE OPEN)
-2.53%
Aug 11, 2025 Earnings Release 2025-08-11 (BEFORE OPEN)
+0.26%
May 28, 2025 Earnings Release 2025-05-28 (BEFORE OPEN)
+0.07%
Feb 06, 2025 Earnings Release 2025-02-06 (BEFORE OPEN)
+2.18%

VOLATILITY & GAP BIAS

AVG GAP MOVE 4.1%
Bullish Gaps (3)
Bearish Gaps (6)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $IMVT

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-30 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 2246m +1.92%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It develops a novel, fully human monoclonal antibody, IMVT-1401, which selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded on July 6, 2018 and is headquartered in…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗